Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards
PET Clinics · 2026-07 · 21 (3) · 383-392
DOI: 10.1016/j.cpet.2026.02.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PET Clinics, 2026-07. Verfasst von Swayamjeet Satapathy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre & Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Ind…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals, Antigens, Surface, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA)-based theranostics represent a paradigm shift in the management of prostate cancer. PSMA-ligand PET/computed tomography has demonstrated superior diagnostic accuracy over conventional imaging across diverse clinical settings. Parallelly, robust phase 3 evidence has established [177Lu]Lu-PSMA-617 radioligand therapy as a standard-of-care in metastatic castration-resistant prostate cancer (mCRPC), with significant improvements in survival end points and quality of life. Emerging data also support the safe and effective integration of [177Lu]Lu-PSMA-617 into earlier disease settings, including chemotherapy-naïve mCRPC and metastatic hormone-sensitive prostate cancer. Collectively, PSMA theranostics exemplify the crucial role of nuclear medicine in advancing precision care for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre & Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, India.
- Department of Nuclear Medicine, Manipal Hospitals, New Delhi, India.
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. Electronic address: nkantdamle@gmail.com.
Zitieren
APA
Satapathy, S., Chandekar, K. R., & Damle, N. A. (2026). Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards. PET Clinics, 21(3), 383-392. https://doi.org/10.1016/j.cpet.2026.02.002
Vancouver
Satapathy S, Chandekar KR, Damle NA. Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards. PET Clinics. 2026;21(3):383-392. doi:10.1016/j.cpet.2026.02.002
BibTeX
@article{Satapathy2026,
author = {Satapathy, Swayamjeet and Chandekar, Kunal R and Damle, Nishikant A},
title = {Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards},
journal = {PET Clinics},
year = {2026},
volume = {21},
number = {3},
pages = {383--392},
doi = {10.1016/j.cpet.2026.02.002}
}
EUVIMED